Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy
Santiago Delgado‐Tirado(Clínica Rementería), Joseph F. Arboleda‐Velásquez(Massachusetts Eye and Ear Infirmary)
Cited by 35
Related Papers
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
|Nature Medicine|2019|606
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study
|Nature Communications|2020|493
Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man
|Nature Medicine|2023|191